Who are Vaniqa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alinia, Pentam, Ameparomo, Clindamycin + primaquine, Eupenta Inj., Propamidine 0.1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eflornithine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vaniqa — Competitive Intelligence Brief

Vaniqa (EFLORNITHINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiprotozoal. Area: Other.

marketed Antiprotozoal Ornithine decarboxylase (ODC) Other Small molecule Live · refreshed every 30 min

Target snapshot

Vaniqa (EFLORNITHINE). Eflornithine inhibits ornithine decarboxylase, reducing polyamine synthesis and affecting cancer cell growth and metabolism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vaniqa TARGET	EFLORNITHINE		marketed	Antiprotozoal	Ornithine decarboxylase (ODC)	1990-01-01
Alinia	NITAZOXANIDE	Romark	marketed	Antiprotozoal [EPC]	Anoctamin-1	2002-01-01
Pentam	PENTAMIDINE	Fresenius Kabi	marketed	Antiprotozoal	Muscarinic acetylcholine receptor M4	1984-01-01
Ameparomo	PAROMOMYCIN		marketed	Antiprotozoal		1969-01-01
Clindamycin + primaquine	Clindamycin + primaquine	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antibiotic + antiprotozoal combination	Bacterial ribosome (clindamycin); protozoal metabolism (primaquine)
Eupenta Inj.	Eupenta Inj.	LG Chem	marketed	Antiprotozoal agent	Parasite DNA and mitochondrial function
Propamidine 0.1%	Propamidine 0.1%	SIFI SpA	phase 3	Antiprotozoal

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiprotozoal class)

· 2 drugs in this class
Fresenius Kabi · 1 drug in this class
SIFI SpA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vaniqa — Competitive Intelligence Brief. https://druglandscape.com/ci/eflornithine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab